Progress in targeting the NLRP3 signaling pathway for inflammatory bowel disease (Review)

Inflammatory caspases pro‑inflammatory cytokines, such as IL‑1β IL‑18, constitute a critical part in the modulation of innate immune responses by the nucleotide‑binding domain leucine‑rich repeat protein (NLRP)3 inflammasome. The NLRP3 inflammasome, a cytosolic complex, is composed of three distinct classes of proteins‑sensor complexes, adaptor proteins, cysteine proteases. It is well‑established that this pathway can powerfully influence the pathophysiology of autoimmune diseases along with an association of a plethora of inflammatory conditions. Therefore, it is of great significance to elucidate the mechanisms through which NLRP3 participates in disease development functions as a potential target for pharmacological intervention. The present review discussed the function role of the NLRP3 inflammasome in inflammatory bowel disease and described the structure assembly and activation mechanism of the NLRP3 inflammasome. Additionally, it explored novel clinical viewpoints and therapeutic advances in targeted NLRP3 inflammasome therapy. In conclusion, the present review offered a comprehensive overview of inflammatory bowel disease and the NLRP3 inflammasome. It is expected to serve as a guide for future research, potentially leading to improved patient outcomes. The present review has been submitted as a pre‑print (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4962722).